9-Carbazolylacetamid | 42892-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-Carbazolylacetamid
• 英文别名: 2-carbazol-9-yl-acetamide；carbazol-9-yl-acetic acid amide；Carbazol-9-yl-essigsaeure-amid；2-Carbazol-9-ylacetamide
• CAS: 42892-30-8
• 化学式: C₁₄H₁₂N₂O
• mdl: MFCD03042411
• 分子量: 224.262
• InChiKey: AYSPMELWNGIEQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 作用下， 生成 9-Carbazolylacetamid
  参考文献：
  名称：

  An application of fuzzy logic reasoning for GIS temporal modeling of dynamic processes

  摘要：

  The analysis and modeling of dynamic processes require the consideration of both spatial and temporal attributes of data and their integration into a GIS database. However, current GIS raster databases have severe limitations related to the temporal component of data. Data are generally stored through a series of snapshot layers associated to particular instants in time. If the interval between two consecutive snapshots is too long the essential information about the change may remain undetected. In this study, spatio-temporal interpolation based on fuzzy logic theory was applied in order to model the missing information about change that happened between consecutive snapshots. Three different scenarios of rural-to-urban landuse transformation were conceived to simulate different dynamics of change using module FUZZY-TEMP integrated in the GRASS4.1 environment. The obtained results were validated through a comparison of the urban boundaries obtained from aerial photographs and those which were generated using the proposed methodology. The results confirm the potential of the approach to produce realistic simulations of the dynamics of the urbanization process. (C) 2000 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0165-0114(99)00013-5

文献信息

• NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Hung David T.

  公开号：US20100022580A1

  公开（公告）日：2010-01-28

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro- 1 H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的三环化合物，可用于调节个体中的组胺受体。其中描述了化合物，包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物。还提供了包含该化合物的制药组合物，以及使用该化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
• 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Medivation Technologies, Inc.

  公开号：US20130190347A1

  公开（公告）日：2013-07-25

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的三环化合物，可用于调节个体中的组胺受体。其中包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物。此外还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190348A1

  公开（公告）日：2013-07-25

  This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本披露涉及新的三环化合物，可用于调节个体中的组胺受体。本文描述了包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物在内的化合物。还提供了包括该化合物的药物组合物，以及使用该化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity
  申请人：Hiroshima University

  公开号：US11071738B2

  公开（公告）日：2021-07-27

  The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明的目的是开发一种治疗脂肪肝（如 NASH 或 NAFLD）的新型治疗剂。 本发明提供了一种治疗或预防脂肪肝的药物，其活性成分包括由式（I）代表的化合物或其药学上可接受的盐。 本发明还提供了一种治疗或预防脂肪肝的药物，其活性成分包括式（I）代表的化合物或其药学上可接受的盐。
• ALTUXOVA L. B.; NIKOLAEVA I. N.; GRINEV A. N., XIMIYA GETEROTSIKL. SOEDIN. <KGSS-AQ>, 1975, HO 7, 954-956
  作者：ALTUXOVA L. B.、 NIKOLAEVA I. N.、 GRINEV A. N.

  DOI：——

  日期：——